Hepatocellular carcinoma in non-alcoholic steatohepatitis

Current knowledge and implications for management

George Cholankeril, Ronak Patel, Sandeep Khurana, Sanjaya Satapathy

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

With the prevalence of hepatitis C virus expected to decline, the proportion of hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is anticipated to increase exponentially due to the growing epidemic of obesity and diabetes. The annual incidence rate of developing HCC in patients with NASH-related cirrhosis is not clearly understood with rates ranging from 2.6%-12.8%. While multiple new mechanisms have been implicated in the development of HCC in NASH; further prospective long-term studies are needed to validate these findings. Recent evidence has shown a significant proportion of patients with non-alcoholic fatty liver disease and NASH progress to HCC in the absence of cirrhosis. Liver resection and transplantation represent curative therapeutic options in select NASHrelated HCC patients but have placed a significant burden to our healthcare resources and utilization. Currently NASH-related HCC is the fastest growing indication for liver transplant in HCC candidates. Increased efforts to implement effective screening and preventative strategies, particularly in non-cirrhotic NASH patients, are needed to reduce the future impact imposed by NASH-related HCC.

Original languageEnglish (US)
Pages (from-to)533-543
Number of pages11
JournalWorld Journal of Hepatology
Volume9
Issue number11
DOIs
StatePublished - Apr 18 2017

Fingerprint

Knowledge Management
Fatty Liver
Hepatocellular Carcinoma
Fibrosis
Hepacivirus
Liver Transplantation
Obesity
Delivery of Health Care
Transplants
Liver
Incidence

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Hepatocellular carcinoma in non-alcoholic steatohepatitis : Current knowledge and implications for management. / Cholankeril, George; Patel, Ronak; Khurana, Sandeep; Satapathy, Sanjaya.

In: World Journal of Hepatology, Vol. 9, No. 11, 18.04.2017, p. 533-543.

Research output: Contribution to journalReview article

@article{b6e1654d754a49e9b669b90ecaf1969d,
title = "Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management",
abstract = "With the prevalence of hepatitis C virus expected to decline, the proportion of hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is anticipated to increase exponentially due to the growing epidemic of obesity and diabetes. The annual incidence rate of developing HCC in patients with NASH-related cirrhosis is not clearly understood with rates ranging from 2.6{\%}-12.8{\%}. While multiple new mechanisms have been implicated in the development of HCC in NASH; further prospective long-term studies are needed to validate these findings. Recent evidence has shown a significant proportion of patients with non-alcoholic fatty liver disease and NASH progress to HCC in the absence of cirrhosis. Liver resection and transplantation represent curative therapeutic options in select NASHrelated HCC patients but have placed a significant burden to our healthcare resources and utilization. Currently NASH-related HCC is the fastest growing indication for liver transplant in HCC candidates. Increased efforts to implement effective screening and preventative strategies, particularly in non-cirrhotic NASH patients, are needed to reduce the future impact imposed by NASH-related HCC.",
author = "George Cholankeril and Ronak Patel and Sandeep Khurana and Sanjaya Satapathy",
year = "2017",
month = "4",
day = "18",
doi = "10.4254/wjh.v9.i11.533",
language = "English (US)",
volume = "9",
pages = "533--543",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "11",

}

TY - JOUR

T1 - Hepatocellular carcinoma in non-alcoholic steatohepatitis

T2 - Current knowledge and implications for management

AU - Cholankeril, George

AU - Patel, Ronak

AU - Khurana, Sandeep

AU - Satapathy, Sanjaya

PY - 2017/4/18

Y1 - 2017/4/18

N2 - With the prevalence of hepatitis C virus expected to decline, the proportion of hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is anticipated to increase exponentially due to the growing epidemic of obesity and diabetes. The annual incidence rate of developing HCC in patients with NASH-related cirrhosis is not clearly understood with rates ranging from 2.6%-12.8%. While multiple new mechanisms have been implicated in the development of HCC in NASH; further prospective long-term studies are needed to validate these findings. Recent evidence has shown a significant proportion of patients with non-alcoholic fatty liver disease and NASH progress to HCC in the absence of cirrhosis. Liver resection and transplantation represent curative therapeutic options in select NASHrelated HCC patients but have placed a significant burden to our healthcare resources and utilization. Currently NASH-related HCC is the fastest growing indication for liver transplant in HCC candidates. Increased efforts to implement effective screening and preventative strategies, particularly in non-cirrhotic NASH patients, are needed to reduce the future impact imposed by NASH-related HCC.

AB - With the prevalence of hepatitis C virus expected to decline, the proportion of hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is anticipated to increase exponentially due to the growing epidemic of obesity and diabetes. The annual incidence rate of developing HCC in patients with NASH-related cirrhosis is not clearly understood with rates ranging from 2.6%-12.8%. While multiple new mechanisms have been implicated in the development of HCC in NASH; further prospective long-term studies are needed to validate these findings. Recent evidence has shown a significant proportion of patients with non-alcoholic fatty liver disease and NASH progress to HCC in the absence of cirrhosis. Liver resection and transplantation represent curative therapeutic options in select NASHrelated HCC patients but have placed a significant burden to our healthcare resources and utilization. Currently NASH-related HCC is the fastest growing indication for liver transplant in HCC candidates. Increased efforts to implement effective screening and preventative strategies, particularly in non-cirrhotic NASH patients, are needed to reduce the future impact imposed by NASH-related HCC.

UR - http://www.scopus.com/inward/record.url?scp=85017540499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017540499&partnerID=8YFLogxK

U2 - 10.4254/wjh.v9.i11.533

DO - 10.4254/wjh.v9.i11.533

M3 - Review article

VL - 9

SP - 533

EP - 543

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 11

ER -